ReMYND lands €3.5M ADDF grant to test Alzheimer's drug in patients

What's the deal? Belgian biotech ReMYND has secured a €3.5 million grant from the Alzheimer's Drug Discovery Foundation (ADDF)Dealroom has a profile for this one. Try Dealroom → to fund clinical development of REM392, its lead candidate for mild-to-moderate Alzheimer's disease. The money will support a Phase 1b study in patients, expected to start in early 2027.

What's the endgame? REM392 is an orally available small molecule designed to counter pathological tau inside neurons. The mechanism, described in Science in 2024, targets septin filaments to restore synaptic function and reduce Alzheimer's pathology.

Why now? The announcement landed on World Alzheimer's Day. The ADDF is a venture philanthropy organisation focused on accelerating drugs to prevent, treat, and cure the disease.

What's the study? The Phase 1b trial will assess safety, tolerability, and pharmacokinetics in symptomatic patients, alongside readouts on cognitive effects and disease progression. "The planned Phase 1b study will put this to the test in patients and generate the next body of evidence," said chief scientific officer Gerard Griffioen.

What could go wrong? ReMYND says the grant alone won't cover the full program. "To generate the full dataset this program needs, including a broad array of exploratory and mechanistic readouts, we are continuing to secure complementary funding," said chief executive officer Floor Stam.

The signal: The grant ranks in the top 10% by size among health-sector grant rounds in Belgium over the past four years, based on 1,739 comparable deals. It reflects growing investor appetite for Alzheimer's approaches that move beyond traditional targets. As the ADDF's Aaron Burstein put it, ReMYND's work helps "broaden the range of therapeutic approaches being developed."

Image credit: ReMYND